Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
March 21st, 2018
10.6K views
Obtaining high-quality genomic DNA from tumor tissues is an essential first step for analyzing genetic alterations using next generation sequencing. In this article, we present a simple and rapid method to enrich tumor cells and obtain intact DNA from touch imprint cytology specimens.
Overview
This article presents a rapid method for obtaining high-quality genomic DNA from tumor tissues using touch imprint cytology specimens. This technique simplifies the process of enriching tumor cells, facilitating genetic analysis through next generation sequencing.
Key Study Components
Area of Science
- Genomic DNA extraction
- Cancer research
- Next generation sequencing
Background
- High-quality DNA is crucial for analyzing genetic alterations.
- Traditional methods for DNA extraction can be complex and time-consuming.
- Touch imprint cytology is a technique that can simplify the process.
- This method allows for quick and efficient collection of tumor DNA.
Purpose of Study
- To develop a simple method for obtaining tumor DNA.
- To enhance the efficiency of genetic analysis in cancer research.
- To provide a reliable protocol for clinical applications.
Methods Used
- Touching the tumor surface onto a glass slide.
- Ensuring coverage of more than 80% of the slide.
- Transferring the imprint to a PEN membrane slide.
- Rubbing the slide gently to collect cells.
Main Results
- The method successfully enriches tumor cells.
- High-quality DNA can be obtained quickly.
- This technique is simpler than previous methods.
- It has potential applications in cancer diagnosis and treatment.
Conclusions
- The protocol offers a rapid approach to DNA extraction.
- It can facilitate important research in cancer genetics.
- This method may improve clinical decision-making in oncology.
Frequently Asked Questions
What is the main advantage of this DNA extraction method?
The main advantage is its simplicity and speed compared to traditional methods.
Can this method be used for all types of tumors?
Yes, it can be adapted for various tumor types as long as the tissue is resected.
Is the quality of DNA obtained sufficient for next generation sequencing?
Yes, the method is designed to yield high-quality DNA suitable for sequencing.
How does touch imprint cytology work?
It involves touching the tumor surface to a slide to collect cells for DNA extraction.
What are the potential applications of this technique?
It can be used in cancer research, diagnosis, and treatment planning.
Is prior experience required to perform this method?
Basic laboratory skills and understanding of cytology are beneficial but not mandatory.
Executive Industry Relevance
Obtaining high-quality tumor DNA is a critical inflection point for molecular profiling and targeted therapy selection in oncology drug development. The touch imprint cytology (TIC) method enables rapid, reliable extraction of intact genomic DNA from clinical specimens, overcoming the limitations of formalin-fixed paraffin-embedded (FFPE) samples. This capability enhances predictive confidence in downstream genetic analyses and accelerates decision-making across discovery and translational pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables robust interrogation of tumor mutational status for target validation.
- Reduces biological ambiguity by providing higher-quality DNA than FFPE samples.
- Supports confident identification of actionable genetic alterations for portfolio triage.
Screening & Assay Development
- Facilitates preparation of validated tumor DNA for next generation sequencing and PCR-based assays.
- Improves assay reproducibility and standardization by ensuring DNA integrity and quantity.
- Enables rapid turnaround for genetic testing, supporting high-throughput screening workflows.
Translational & Preclinical Research
- Aligns with disease-relevant biomarker discovery by preserving tumor-specific genetic signatures.
- Ensures continuity from clinical sample acquisition to preclinical model validation.
- De-risks translational research by minimizing sample degradation and data loss.
Pipeline & Workflow Integration
The TIC method integrates at the interface of clinical sample acquisition and molecular analysis, supporting workflows from early discovery through translational research.
- Discovery Biology: Provides high-integrity DNA for hypothesis testing and pathway analysis.
- Screening: Delivers reproducible, quantitative DNA inputs for sequencing and PCR assays.
- Analytics: Enables accurate measurement of mutational status and DNA quality metrics (e.g., RQ value).
- Translational Research: Maintains genetic fidelity for biomarker and mechanistic studies.
- Enterprise Reuse: Offers a standardized, rapid protocol adaptable across tumor types and research sites.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in genetic analyses.
- Operational Value: Streamlines DNA extraction with rapid, reproducible workflows and minimal sample loss.
- Strategic Value: Accelerates go/no-go decisions and reduces late-stage risk by improving data quality.
- Portfolio Impact: Supports risk-adjusted prioritization of molecular targets and candidate therapies.
Implementation Considerations
- Requires expertise in cytological assessment and DNA extraction protocols.
- Needs access to microscopy, PEN membrane slides, and sequencing instrumentation.
- Demands cross-team standardization for sample handling and quality assessment.
- Adaptable to various tumor types but dependent on sufficient tumor cellularity.
- Limited by the need for resected tissue and initial cytological evaluation.
Biopharma FAQs
Why does null hypothesis testing matter for TIC-based target validation?
Null hypothesis testing using TIC-derived DNA ensures that observed genetic alterations are statistically significant and not due to sample degradation or contamination, supporting robust target validation decisions in oncology pipelines.
How does independent variable isolation fit the TIC DNA extraction workflow?
Isolating tumor cellularity as an independent variable in TIC specimens allows precise assessment of DNA quality and quantity, enabling controlled comparisons across samples and enhancing discovery-stage rigor.
What do quantitative dependent variable measurements enable in TIC DNA analysis?
Quantitative measurements such as DNA yield and RQ value from TIC samples enable objective evaluation of sample integrity, supporting reliable downstream sequencing and mutation detection for translational research.
Why are replication requirements critical for cross-functional TIC DNA workflows?
Replication of TIC DNA extraction and analysis ensures reproducibility and comparability across research teams, facilitating cross-functional collaboration and consistent data quality in multi-site studies.
What statistical analysis capabilities are required before TIC DNA implementation?
Robust statistical analysis of DNA quality metrics and mutation concordance between TIC and FFPE samples is essential to validate TIC as a reliable alternative, supporting confident adoption in biopharma R&D workflows.
